CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

Clinical trial NCT03739554 · COMPLETED

Trial details

NCT number: NCT03739554
Sponsor: Cyclacel Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed or Refractory Chronic Lymphocytic Leukemia

Start date: 2019-01-25
Primary completion: 2022-11-15
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.